. CAR T-cell therapies are FDA approved for:
- Aggressive relapsed or refractory large B-cell lymphoma including diffuse large B cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, high-grade B-cell lymphoma, and transformed follicular lymphoma.
- Relapsed or refractory mantle cell lymphoma
- Relapsed or refractory follicular lymphoma